A Prospective, Multi-center Registry to Evaluate Safety and Efficacy of Hativ® ELectrocardiogram Monitoring on Patients with Hemodialysis

NARecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

May 13, 2025

Study Completion Date

December 31, 2025

Conditions
End-Stage Kidney DiseaseHemodialysis
Interventions
DEVICE

Hativ® electrocardiogram monitoring

Using Hativ®, a currently commercially available class II medical device, ECGs are measured every day at home and before and after dialysis

Trial Locations (1)

Unknown

RECRUITING

Hallym University Sacred Heart Hospital, Anyang

All Listed Sponsors
lead

Hallym University Medical Center

OTHER